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Cognitive impairments are a prevalent and disabling non-motor complication of Parkinson’s disease, but with variable expression
and progression. The onset of serious cognitive decline occurs alongside substantial cholinergic denervation, but imprecision of
previously available techniques for in vivo measurement of cholinergic degeneration limit their use as predictive cognitive bio-
markers. However, recent developments in stereotactic mapping of the cholinergic basal forebrain have been found useful for
predicting cognitive decline in prodromal stages of Alzheimer’s disease. These methods have not yet been applied to longitudinal
Parkinson’s disease data. In a large sample of people with de novo Parkinson’s disease (n = 168), retrieved from the Parkinson’s
Progressive Markers Initiative database, we measured cholinergic basal forebrain volumes, using morphometric analysis of
T1-weighted images in combination with a detailed stereotactic atlas of the cholinergic basal forebrain nuclei. Using a binary
classiﬁcation procedure, we deﬁned patients with reduced basal forebrain volumes (relative to age) at baseline, based on volumes
measured in a normative sample (n = 76). Additionally, relationships between the basal forebrain volumes at baseline, risk of later
cognitive decline, and scores on up to 5 years of annual cognitive assessments were assessed with regression, survival analysis and
linear mixed modelling. In patients, smaller volumes in a region corresponding to the nucleus basalis of Meynert were associated
with greater change in global cognitive, but not motor scores after 2 years. Using the binary classiﬁcation procedure, patients
classiﬁed as having smaller than expected volumes of the nucleus basalis of Meynert had 3.5-fold greater risk of being categorized
as mildly cognitively impaired over a period of up to 5 years of follow-up (hazard ratio = 3.51). Finally, linear mixed modelling
analysis of domain-speciﬁc cognitive scores revealed that patients classiﬁed as having smaller than expected nucleus basalis volumes
showed more severe and rapid decline over up to 5 years on tests of memory and semantic ﬂuency, but not on tests of executive
function. Thus, we provide the ﬁrst evidence that volumetric measurement of the nucleus basalis of Meynert can predict early
cognitive decline. Our methods therefore provide the opportunity for multiple-modality biomarker models to include a cholinergic
biomarker, which is currently lacking for the prediction of cognitive deterioration in Parkinson’s disease. Additionally, ﬁnding
dissociated relationships between nucleus basalis status and domain-speciﬁc cognitive decline has implications for understanding
the neural basis of heterogeneity of Parkinson’s disease-related cognitive decline.
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Introduction
Cognitive impairment is a major non-motor complication
of Parkinson’s disease and is associated with signiﬁcant
disability and reduced quality of life (Lawson et al.,
2016). The estimated one-third of patients with
Parkinson’s disease who have cognitive impairment even
very early in the disease (Foltynie et al., 2004) have an
increased risk of developing Parkinson’s disease dementia
within a short timeframe (Foltynie et al., 2004; Janvin
et al., 2006). However, early cognitive impairments in
Parkinson’s disease are complex and multifarious; individ-
ual patients experience impairments in different cognitive
domains, with variable onset, severity and progression
rates (Kehagia et al., 2013). Yet, the development of inter-
ventions that could delay the onset of Parkinson’s disease
dementia depends on accurate prognostication of individual
patients at early disease stages, making the development of
predictive biomarkers a critical area of Parkinson’s disease
research.
Fortunately, longitudinal clinical data—in part collected
through large-scale, multicentre initiatives—are beginning
to reveal clinical, genetic, molecular, neuroimaging and
electrophysiological biomarkers that can predict the rate
and severity of cognitive decline in Parkinson’s disease
(Dujardin et al., 2004; Williams-Gray et al., 2009a, b,
2013; Siderowf et al., 2010; Bohnen et al., 2011; Chen-
Plotkin et al., 2011; Klassen et al., 2011; Weintraub
et al., 2011; Mak et al., 2015; Schrag et al., 2017). Most
recently, Schrag et al. (2017), using data collected as part
of the Parkinson’s Progressive Marker’s Initiative (PPMI),
an ongoing multicentre longitudinal study in Parkinson’s
disease, reported that a simple algorithm combining age,
sensory, behavioural, biological, and neuroimaging markers
at the time of Parkinson’s disease diagnosis can predict
global cognitive decline after 2 years. Progress in this
ﬁeld has huge implications for understanding the patho-
physiology of cognitive decline and Parkinson’s disease de-
mentia, and for stratiﬁcation of at-risk participants in
clinical trials. However, given the known involvement of
the cholinergic system in Parkinson’s disease-related cogni-
tive impairments (Candy et al., 1983; Liu et al., 2015), the
absence of cholinergic biomarkers in these studies is a
recognized omission (Caspell-Garcia et al., 2017).
Previous work has aimed to understand the pattern of
cognitive impairments across different cognitive domains in
Parkinson’s disease, and whether these relate differentially to
the development of Parkinson’s disease dementia (Williams-
Gray et al., 2009a). A synthesis of research in this ﬁeld led
to a ‘dual-syndrome’ hypothesis (Kehagia et al., 2013). This
posits that a distinction can be made between fronto-striatal
executive impairments that are dopaminergically mediated,
and which may not herald the progression of serious cogni-
tive decline, and a dementia syndrome typiﬁed by choliner-
gically-mediated memory and visuospatial deﬁcits associated
with posterior cortical and temporal lobe dysfunction.
Evidence for this idea is accumulating from large-scale lon-
gitudinal studies, which have additionally implicated distinct
genetic contributions to the two syndromes (Williams-Gray
et al., 2009a, b, 2013). Importantly, these ﬁndings imply
that effective biomarkers will predict different long-term cog-
nitive outcomes for dissociated cognitive syndromes.
Structural and functional neuroimaging can be usefully
incorporated with genetic and neuropsychological markers
to better understand cognitive symptom heterogeneity in
Parkinson’s disease (for reviews see Shi et al., 2010;
Baggio et al., 2015; Strafella et al., 2017). In particular,
imaging of grey matter volume reductions in Parkinson’s
disease offers a relatively low cost, widely available and
non-invasive procedure that can reveal the cortical and sub-
cortical changes associated with cognitive symptom pro-
gression (Weintraub et al., 2011; Hanganu et al., 2014;
Lee et al., 2014a). Recent longitudinal work has revealed
that mild cognitive impairment (MCI) in Parkinson’s dis-
ease is associated with the development of more widespread
cortical atrophy than in those with normal cognition (Mak
et al., 2015). In that study, the MCI group had atrophy
extending from frontal regions to posterior temporal cor-
tices over 18 months of follow-up, potentially reﬂecting
additional pathophysiological processes including multisys-
tem neurotransmitter decline.
In early work on cognitive decline in Parkinson’s disease,
autopsy studies identiﬁed degeneration of the cholinergic
basal forebrain (cBF), in particular the nucleus basalis of
Meynert (NBM), and ensuing cortical cholinergic depletion
as major determinants of cognitive complications. This rep-
resents a neuropathological feature Parkinson’s disease
shares with Alzheimer’s disease dementia (Candy et al.,
1983; Liu et al., 2015). Previous efforts to study the struc-
tural status of the cBF in vivo on MRI scans have relied on
manual delineation of a relatively gross anatomical region
identiﬁed by the grey matter ventral to the crossing of the
anterior commissure as an external landmark, typically
termed ‘substantia innominata’. In Parkinson’s disease de-
mentia, cBF degeneration has been hitherto detected in vivo
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as volumetric reduction of the substantia innominata (Choi
et al., 2012). Structural changes of this region have also
been identiﬁed in non-demented Parkinson’s disease pa-
tients, and shown to be predictive of imminent conversion
from MCI to Parkinson’s disease dementia (Lee et al.,
2014b). However, there is little exploration of how
volume reductions in the cBF and its functionally and ana-
tomically distinct subdivisions are related to current or sub-
sequent cognitive decline in newly diagnosed Parkinson’s
disease patients.
Recent developments in stereotactic mapping of the cBF
nuclei in the human brain have rendered this region access-
ible to detailed MRI-based morphometric assessments, pro-
viding an in vivo surrogate marker of cBF structural
integrity (Kilimann et al., 2014). These novel methods
have been informative in Alzheimer’s disease research, re-
vealing that subregional cBF degeneration (in particular
posterior parts of the NBM) can already be detected at
predementia stages of the disease, where it is associated
with emerging cognitive deﬁcits (Grothe et al., 2010,
2012, 2013, 2016; Schmitz and Spreng, 2016). Such ﬁnd-
ings offer hope that a more detailed analysis of cBF struc-
ture than has been available so far may provide an early
marker for cognitive impairments and future dementia even
in de novo Parkinson’s disease.
In non-demented Parkinson’s disease, as expected given
considerable heterogeneity of cognitive symptoms, choliner-
gic denervation revealed by in vivo PET imaging is variable
(Bohnen et al., 2012, 2015). Thus, in analogy to the ap-
proach in Bohnen et al. (2015) we use a binary classiﬁca-
tion method to deﬁne participants with newly diagnosed
Parkinson’s disease with reduced cBF volumes (based on
a normative sample), measured using detailed MRI-based
morphometry based on stereotactic mappings of cBF nuclei.
Additionally, we track the cognitive status of participants
classiﬁed as having reduced or within normal range cBF
volumes at Parkinson’s disease diagnosis over a period of
up to 5 years to determine the predictive utility of this
distinction for the development of cognitive decline.
Patients and methods
Study design
The PPMI is a longitudinal, multicentre study to assess pro-
gression of clinical features, imaging and biological markers in
patients with Parkinson’s disease (de novo Parkinson’s disease,
prodromal and subjects with speciﬁc genetic mutations) and
healthy controls. It is a public-private partnership funded by
the Michael J. Fox Foundation for Parkinson’s research and
funding partners, a full list of whom can be found at www.
ppmi-info.org/fundingpartners.
To enrol in the study, participants with Parkinson’s disease
must have had a diagnosis of Parkinson’s disease for 2 years or
less at the screening visit, and be at Hoehn and Yahr stage I or
II at the baseline visit. Participants are also not expected to
require Parkinson’s disease medication within at least 6
months from the baseline visit. Control participants were
excluded if they had a ﬁrst-degree relative with idiopathic
Parkinson’s disease or a Montreal Cognitive Assessment
(MoCA) score 526. The inclusion criteria for the PPMI data-
base are described in detail in the PPMI study documents
available at http://www.ppmi-info.org/data. For up-to-date in-
formation on the study, visit www.ppmi-info.org.
Participants
Participants selected from the PPMI for the current study were
all those with T1 MRI scans available at 3T, acquired on Tim
Trio 3T scanners (Siemens), and with acquisition parameters
as described below. These were 172 participants with
Parkinson’s disease and 76 control participants, who had
been recruited at 11 centres worldwide.
Following manual investigation of brain images (see ‘MRI
preprocessing’ section), four Parkinson’s disease brain images
were removed. Thus, of the 168 Parkinson’s disease patients
with baseline neuroimaging and at least partial cognitive data
(i.e. scores available on at least the MoCA at baseline), 143,
149, 144, 122 and 53 had at least partial cognitive data at 1-,
2-, 3-, 4- and 5-year follow-up visits, respectively.
Motor, cognitive and clinical
assessments
Alongside the Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS) for motor symptom severity, and the MoCA, the
cognitive status of participants in the PPMI was categorized
by study clinicians as normal cognition, MCI, or Parkinson’s
disease dementia based on Level 1 criteria developed by the
Movement Disorder Society (Litvan et al., 2012). In brief, MCI
was determined by the following factors: cognitive complaint
by either the patient or informant (spouse, family member or
friend), at least two test scores (of the six reported below) from
at least one domain with 41.0 standard deviation (SD) below
the standardized mean, and no functional impairment as a
result of cognitive impairment. Parkinson’s disease dementia
was determined as cognitive impairment deﬁned as at least
one test score from two domains 41.5 SD below the standar-
dized mean along with functional impairment due to cognitive
impairment. A full description of these methods is available at
http://www.ppmi-info.org/study-design/research-documents-
and-sops/.
This element of the PPMI was implemented at a late stage,
meaning that many patients only have cognitive categorization
from 2-year follow-up visit onwards. Thus, to compare cBF
volumes between patients with and without evidence of cogni-
tive impairment at baseline, we applied the thresholding cri-
teria for MCI to patients’ baseline cognitive task scores. Since
we do not have information on patient/informant complaint of
cognitive impairment at this time point, we applied a more
stringent threshold of 41.5 SD below the control sample’s
mean. Patients falling below these criteria were deﬁned as ‘sus-
pected MCI’, to reﬂect the lower level of conﬁdence in this
classiﬁcation.
In secondary analyses we assessed the cognitive domain spe-
ciﬁcity of reduced cBF volume by examining scores on each of
the separate cognitive tests employed in the PPMI. These were
the Hopkins Verbal Learning Test (HVLT) (immediate and
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delayed recall memory), semantic ﬂuency (language), the
Benton test of line orientation (visuospatial ability), the
Symbol Digit Substitution test (attention/working memory)
and the Letter Number Sequencing task (attention/working
memory). Scores on these tests were collected at baseline and
all available annual follow-up visits up to 5 years from
enrolment.
MRI acquisition
MRI data acquisition was performed, across multiple centres,
on Tim Trio 3T scanners (Siemens). High-resolution structural
images were collected by using a 3D magnetization-prepared
rapid acquisition gradient echo (MP-RAGE) T1-weighted se-
quence with the following parameters: sagittal section thick-
ness, 1.0mm; no gap; repetition time, 2300ms; echo time,
2.98ms; ﬂip angle, 9; ﬁeld of view, 240  256mm; matrix
size, 240  256; inversion time, 900ms; voxel size,
1  1  1mm3. The image plane aligned in the sagittal plane
along the hemispheric ﬁssure and axially along the anterior/
posterior commissure plane. The 176 sections covered the
entire brain from ear to ear and the bottom of the cerebellum
to the vertex.
Stereotactic map of the cholinergic
basal forebrain
The cBF map was created using stereotactic mapping of cBF
nuclei as described in Kilimann et al. (2014). In brief, the map
was derived from combined post-mortem MRI and subsequent
histological preparation of a brain specimen of a 56-year-old
male who had died without any evidence of cognitive decline
or psychiatric illnesses. Cerebral MRI scans were performed in
situ 15 h after death as well as after the brain was removed
from the skull and dehydrated for histological preparation.
Cholinergic nuclei were identiﬁed and delineated on digital
pictures of the stained brain slices following Mesulam’s no-
menclature (Mesulam et al., 1983), and the cBF regions iden-
tiﬁed on the histological slices were manually transferred from
the digital pictures into the corresponding magnetic resonance
slices of the dehydrated brain. Transformation of the delinea-
tions from the space of the dehydrated brain into the space of
the in situ brain scan was based on an initial 12-parameter
afﬁne transformation followed by a high-dimensional non-
linear registration between the two brain scans (Ashburner
and Friston, 1999). The improved grey–white matter contrast
of the in situ brain scan enabled the use of the highly accur-
ate high-dimensional DARTEL (Diffeomorphic Anatomic
Registration using Exponentiated Lie algebra) registration
method (Ashburner, 2007; Klein et al., 2009) for the ﬁnal
transformation from in situ space into Montreal
Neurological Institute (MNI) standard space. The stereotactic
cBF map distinguishes different cholinergic subdivisions within
the basal forebrain, including cell clusters corresponding to the
medial septum, vertical and horizontal limb of the diagonal
band, and NBM (Ch1–4 according to Mesulam’s nomencla-
ture; Mesulam et al., 1983) (Fig. 1).
MRI preprocessing
Scans acquired at baseline were downloaded from the PPMI in
May 2016. Following our previously established method for
MRI-based cBF volumetry (Grothe et al., 2012, 2014, 2016),
the T1 scans were automatically segmented into grey matter,
white matter, and CSF partitions of 1.5-mm isotropic voxel
size using the segmentation routine of the VBM8 toolbox
(http://www.neuro.uni-jena.de/vbm/download/) running under
SPM8 (http://www.ﬁl.ion.ucl.ac.uk/spm/software/spm8/). The
resulting grey and white matter partitions of each subject in
native space were then high-dimensionally registered to MNI
space using DARTEL (Ashburner, 2007). The grey matter seg-
ments were then warped using the individual ﬂow ﬁelds result-
ing from the DARTEL registration, and voxel values were
modulated for volumetric changes introduced by the high-di-
mensional normalization. Thus, the total amount of grey
matter volume present before warping was preserved. All pre-
processed grey matter maps were required to pass a visual
inspection for overall segmentation and registration accuracy.
Four participants (in the Parkinson’s disease group) did not
pass this inspection, and therefore their data were removed
from further analyses.
Subregional cBF grey matter volumes were calculated by
summing up the modulated grey matter voxel values within
the respective region of interest masks in template space
(Ashburner, 2009). These volumes and global grey matter
Figure 1 Cholinergic basal forebrain regions of interest. Full details of how the subregional cBF map was generated can be found in
Kilimann et al. (2014). The regions of interest have been superimposed on the T1-weighted high-resolution ICBM 2009a Nonlinear Asymmetric
MNI152 standard space template available at http://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009. Slices from left to right are coronal
slices 8, 3, 6, 9. Red represents the Ch1-2 region of interest corresponding to the medial septum and vertical limb of the diagonal band, green is
the nucleus subputaminalis/anterior-lateral NBM and the horizontal limb of the diagonal band (not selected as an region of interest in the current
paper), Light blue + dark blue represents the Ch4 region of interest corresponding to the NBM, and dark blue represents the Ch4p region of
interest corresponding to the posterior NBM.
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were further scaled (by ANCOVA) to total intracranial
volume, calculated as the sum of total grey matter, white
matter and CSF volumes, as a proxy for head size. We con-
sidered two distinct subdivisions of the cBF that can be clearly
separated anatomically, and are characterized by differential
cortical projection preferences and associations with speciﬁc
cognitive and behavioural functions (Mesulam et al., 1983;
Muir, 1997; Zaborszky et al., 2015). These correspond to an
anterior-medial cBF region of interest that combines the medial
septum (Ch1) and the vertical limb of the diagonal band
(Ch2), and a more posterior region of interest covering the
NBM (Ch4). Additionally, hypothesis-driven analyses were
applied to a posterior NBM subdivision (Ch4p) given that
previous in vivo analyses in MCI and Alzheimer’s disease
have found a particular involvement of this region (Grothe
et al., 2012, 2013; Kilimann et al., 2014), which is consistent
with neuropathological evidence for a subregion-speciﬁc vul-
nerability to Alzheimer’s disease-related neurodegeneration
(Vogels et al., 1990).
Identification of participants with
cholinergic basal forebrain volumes
below the range in controls
To deﬁne participants with cBF volumes outside the range of
controls, linear regression models were constructed to predict
regional cBF volumes from total intracranial volume and age
in the control sample (sex was not a signiﬁcant contributor in
any of these models and was therefore not included in the ﬁnal
models). These models were able to signiﬁcantly predict vol-
umes in all cBF regions, with R2 values between 0.69 and
0.74. Beta weights from these regressions were used to calcu-
late expected cBF volumes in the Parkinson’s disease sample,
and participants with cBF volumes below/above the lower
68% conﬁdence limit (corresponding to 1 SD) of the control
sample were classiﬁed as having reduced/normal-range cBF
volumes, subsequently referred to as the cBF and cBF+
Parkinson’s disease groups, respectively.
Statistical analysis
General linear model-based statistical analyses were conducted
in SPSS statistics 22 and MatLab r2016a. Linear mixed model
analyses were carried out in STATA/SE 14.2.
Baseline cholinergic basal forebrain volumes, demo-
graphics and clinical scores
T-tests and univariate analyses (controlling for age, sex and
disease duration) were used to compare demographics, clinical
and cognitive measures, and total intracranial volume-normal-
ized cBF region of interest volumes between control and
Parkinson’s disease participants, and between control subjects
and patients with Parkinson’s disease with and without sus-
pected MCI. Pearson’s partial correlations controlling for age,
sex and disease duration were computed for the relationship
between volume of each cBF region of interest and motor
assessment.
Baseline cholinergic basal forebrain volumes, MoCA
scores and cognitive categorization with longitudinal
follow-up
Hierarchical multiple regression models were constructed to
determine the predictive utility of baseline cBF volumes on
change in MoCA scores (from baseline) at the 2-year follow-
up visit, with age, sex, disease duration and baseline MoCA
scores entered simultaneously in the ﬁrst step, and cBF vol-
umes entered in the second.
In addition, Cox proportional hazards regression analysis
was performed to model the risk of MCI or Parkinson’s dis-
ease dementia over the available follow-up period as a func-
tion of being classiﬁed as either cBF or cBF+ at baseline (with
each region of interest included in separate Cox regressions).
Time to event (categorization of MCI or Parkinson’s disease
dementia) was calculated as the number of months since
Parkinson’s disease diagnosis until an MCI or Parkinson’s dis-
ease dementia classiﬁcation was made. MCI classiﬁcations
based on Level 1 MDS criteria can ﬂuctuate in early disease
stages (Lawson et al., 2017), with patients frequently being
later classiﬁed as normal cognition. To mitigate the potential
for misdiagnosis, patients with MCI classiﬁcations on a single
visit, who were subsequently and consistently classiﬁed as
normal cognition (provided at least two subsequent visits
were available to conﬁrm normal cognition classiﬁcation)
were deemed to be normal cognition at the end of their avail-
able visits. Nine patients without full cognitive testing on visits
following baseline could not be included. Additional covariates
entered into the model were age, gender, baseline MoCA scores,
disease duration and total intracranial volume-normalized
global grey matter volumes. Due to many patients’ ﬁrst cogni-
tive categorizations being made at the 2-year visit, there were 30
patients with MCI or Parkinson’s disease dementia at their ﬁrst
categorization, meaning we could not be sure that patients did
not already meet the criteria for MCI at baseline. Thus, the Cox
regression was repeated in a more restricted sample to ensure
classiﬁcation as cBF+/cBF was predictive of future cognitive
decline, and did not depend on patients who may have deterio-
rated cognitively very early in their disease. In the repeated ana-
lysis, the criteria for suspected MCI (deﬁned above) were
applied at the baseline visit, and only participants without sus-
pected MCI were included. Subject numbers contributing to
each of the Cox regressions are reported in the ‘Results’ section
to avoid confusion.
Baseline cholinergic basal forebrain volumes and
domain-specific cognitive assessments with
longitudinal follow-up
For cBF regions of interest showing a signiﬁcant effect for
predicting changes in MoCA or cognitive categorization
(MCI/Parkinson’s disease dementia), linear mixed modelling
was used to investigate the mean decline in scores on the full
PPMI cognitive battery over time (up to 5 years) in the cBF
and cBF+ groups, controlling for global grey matter, age, sex
and disease duration. Mixed effects models with maximum
likelihood estimators were used. Such an approach is preferred
as it can effectively handle the hierarchical nature of longitu-
dinal, repeated-measures data, and does not require list-wise
deletion in cases with missing values, as is the case with stand-
ard general linear models. Separate models for each cognitive
test used test scores as outcome variables, and a ﬁrst order
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polynomial (linear time), group (cBF or cBF+), and the inter-
action between the two as ﬁxed effects predictors. The random
part of all models included participant ID and a ﬁrst order
polynomial. All models allowed for the intercept (cognition
at baseline) and slope (the rate of change) to vary across indi-
viduals. Values reported are unstandardized beta values with
95% conﬁdence intervals (CI).
Correction for multiple comparisons
All analyses that included the Ch1-2 and Ch4 regions of inter-
est were Benjamini-Hochberg corrected for multiple compari-
sons across the two regions. For Ch4p, which has previously
been implicated in Alzheimer’s disease-related degeneration
(Grothe et al., 2012, 2013; Kilimann et al., 2014), results
were considered signiﬁcant at P50.05 (two-tailed). We did
not have region-speciﬁc predictions in control subjects, there-
fore Benjamini-Hochberg corrections were applied for multiple
comparisons across the three cBF regions of interest. For be-
tween-group (cBF+/cBF) comparisons of progressive decline
on the domain-speciﬁc cognitive tasks, Benjamini-Hochberg
corrections were applied for multiple comparisons across the
six tasks assessed. To avoid confusion, corrected P-values are
noted in the ‘Results’ section.
Results
Control subjects versus patients with
Parkinson’s disease at baseline
There were no signiﬁcant differences in age or gender be-
tween participants with Parkinson’s disease and healthy con-
trol subjects (Table 1). As expected, in univariate
comparisons controlling for age and sex, participants with
Parkinson’s disease had signiﬁcantly greater total scores on
the UPDRS [F(1,238) = 22.25, P5 0.001], and had a greater
degree of cognitive impairment as measured on the MoCA
[F(1,240) = 7.58, P = 0.006].
On domain-speciﬁc assessments at baseline, Parkinson’s
disease patients had worse scores on the Symbol Digit
Modalities task: [F(1,237) = 11.43, P = 0.001]; and a ten-
dency for poorer scores on the Letter-Number Sequencing
[F(1,237) = 3.03, P = 0.08] and Benton task [F(1,237) =
3.58, P = 0.06]. Performance was not signiﬁcantly different
to controls on all other tests: memory [immediate recall,
F(1,237) = 0.26, P = 0.61; delayed recall, F(1,237) = 0.12,
P = 0.28], semantic ﬂuency [F(1,237) = 2.04, P = 0.16].
In both groups, age was signiﬁcantly correlated with all
total intracranial volume-normalized cBF regional volumes
(Controls: r40.46, P5 0.001 in all regions; Parkinson’s
disease: r40.49; P5 0.001 in all regions). After control-
ling for age and sex, univariate tests revealed there were no
signiﬁcant differences in Ch1-2, Ch4 or Ch4p volume be-
tween controls and participants with Parkinson’s disease as
a whole [Ch1-2: F(1,240) = 0.41, P = 0.52 corrected; Ch4:
F(1,240) = 0.09, P = 0.76 corrected; Ch4p: F(1,240) = 1.81,
P = 0.19]. However, in univariate tests comparing cBF
region of interest volumes between controls and
Parkinson’s disease patients with, and without suspected
MCI at baseline, we found smaller Ch4p [F(2,236) = 3.09
P = 0.047], but not Ch4 or Ch1-2 volumes [Ch1-2:
F(2,236) = 0.72, P = 0.48; Ch4: F(2,236) = 2.25, P = 0.11].
Post hoc tests revealed group differences in the Ch4p region
were restricted to comparisons between controls and
Parkinson’s disease patients with suspected MCI
[F(1,98) = 6.95, P = 0.01; Fig. 2].
There were no signiﬁcant partial correlations (controlling
for age, sex and disease duration) between cBF volumes
and Parkinson’s disease patients’ scores on the UPDRS
part III (r50.12, P4 0.22 in all regions).
Table 1 Participant characteristics
Healthy controls Parkinson’s disease
n = 76, female = 26 n = 168, female = 63
Mean SD Mean SD
Age, years 59.89 10.18 61.52 9.42
Disease duration, months 7.23 7.52
UPDRS-MDS* 3.47 3.67 30.79 13.06
MoCA
At baseline* 28.25 1.16 27.49 2.13
At 2-year follow-up* 27.46 2.18 26.66 2.74
HVLT (immediate recall) 25.66 4.42 25.21 5.25
HVLT (delayed recall) 9.08 2.29 8.67 2.49
Letter number sequencing 11.39 2.46 10.65 2.79
Symbol digit substitution* 46.59 9.96 41.78 9.7
Semantic fluency 51.72 10.53 49.52 11.3
Benton JLO 13.41 1,57 12.85 2.01
HVLT = Hopkins Verbal Learning Test; JLO = judgement of line orientation; UPDRS = Unified Parkinson’s Disease Rating Scale-Movement Disorder Society.
*Significantly different between participants with Parkinson’s disease and healthy controls at P5 0.05 (age corrected).
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Baseline cholinergic basal forebrain
volumes and longitudinal MoCA
scores
In controls, a hierarchical linear regression analysis with
age, sex and baseline MoCA entered as a ﬁrst step revealed
there was no signiﬁcant relationship between change in
MoCA scores after 2 years and volumes of any cBF
region of interest (b50.22, P4 0.12 in all regions).
In contrast, in Parkinson’s disease, Ch4 and Ch4p volumes,
but not Ch1-2 volumes, were a signiﬁcant predictor of 2-year
change in MoCA score after controlling for age, sex, disease
duration and baseline MoCA score (Ch4: b = 0.23,
R2 = 0.26, P = 0.04 corrected; Ch4p: b =0.20, P = 0.04;
Ch1-2: b = 0.15, P = 0.07 corrected).
Binary cBF/cBF+ classifications at
baseline and longitudinal cognitive
categorizations
For each of the examined cBF regions of interest, Ch1-2,
Ch4 and Ch4p, there were 32, 33, and 32 participants with
Parkinson’s disease, respectively, who had regional volumes
that were smaller than expected given the control range. As
well as smaller regional cBF volumes, global grey matter
volumes were lower in the cBF groups for each region
(Ch1-2: t = 6.12; P5 0.001 corrected; Ch4: t = 4.97;
P50.001 corrected; Ch4p: t = 3.07; P = 0.003). As
such, global grey matter is included as a covariate in all
subsequent analyses. Different, but partially overlapping,
participants were identiﬁed as cBF and cBF+ when clas-
siﬁcations were based on the different regions of interest:
participants with smaller volumes in all three regions:
n = 14; in two regions: n = 14; in one region only: n = 27.
Cox proportional hazards models revealed that age and
global grey matter were independently associated with
increased risk of being categorized as MCI or Parkinson’s
disease dementia (age: Wald = 4.93, P = 0.03; global grey
matter: Wald = 14.02, P5 0.001). Classiﬁcation as cBF/
cBF+ in the Ch1-2 (n = 29/129) and Ch4p regions did not
signiﬁcantly alter risk (Ch1-2: Wald = 0.25, P = 0.87 cor-
rected; Ch4p (n = 29/129): Wald = 0.56, P = 0.45).
However, addition of cBF+/cBF classiﬁcation to the
model revealed that having smaller than expected Ch4
volume (n = 30/128) did add independently to risk of
being diagnosed with MCI or Parkinson’s disease
dementia (Wald = 10.36, P = 0.002 corrected, hazard
ratio = 3.51) (Fig. 3). Restricting this analysis to only
patients without suspected MCI at baseline revealed that
classiﬁcation as Ch4  (n = 23/112) continued to incur
risk for future MCI (Wald = 5.60, P = 0.02, hazard
ratio = 3.00).
Given these results, in all further analyses, classiﬁcations
as cBF or cBF+ are based only on volumes in the Ch4
region.
Figure 3 Survival function for categorization as MCI or
Parkinson’s disease dementia in cBF and cBF+ patients.
Cox proportional hazards survival functions for months between
diagnosis of Parkinson’s disease and categorization as MCI or
Parkinson’s disease dementia, separated by cBF (green) versus
cBF+ (blue) status for the Ch4 region (i.e. patients with Parkinson’s
disease with reduced volumes in the NBM versus those with vol-
umes within range of controls, respectively). PD = Parkinson’s dis-
ease; ROI = region of interest.
Figure 2 Box plot of cBF region of interest volumes at
baseline in controls and Parkinson’s disease patients with
and without suspected MCI. CBF region of interest volumes in
controls, patients with Parkinson’s disease with and without sus-
pected MCI, with the Ch4p region (corresponding to the posterior
NBM) being significantly different between controls and Parkinson’s
disease patients with suspected MCI.
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Domain-specific cognitive tests in
cBF and cBF+ patients
The cBF and cBF+ groups were of similar age (t = 0.56,
P = 0.58). Linear growth curve models evaluated dissociations
in progressive decline over 5 years in cognitive scores between
the cBF and cBF+ groups. When controlling for global grey
matter, age, sex and disease duration, and following false
discovery rate correction for the six tests measured, these ana-
lyses revealed that scores on all tasks were not signiﬁcantly
different between the groups at baseline [MoCA: b = 0.08
(0.81, 0.97), P = 0.868; delayed recall: b = 0.30 (0.77,
1.37), P = 0.577; immediate recall: b = 0.42 (1.72, 2.57),
P = 0.700; semantic ﬂuency: b = 1.34 (5.81, 3.13),
P = 0.556; Benton: b = 0.75 (1.58, 0.08), P = 0.075;
Symbol-digit Substitution: b =4.16 (7.77, 0.55),
P = 0.168; letter number sequencing b = 0.29 (0.67, 1.24),
P = 0.558]. However, scores on the MoCA, delayed and im-
mediate recall, and semantic ﬂuency declined signiﬁcantly
faster in the cBF group [MoCA: b = 0.45 (0.74,
0.15), P = 0.003; immediate recall: b = 0.37 (0.59,
0.14), P = 0.002; delayed recall: b = 0.74 (1.17,
0.31), P = 0.001; semantic ﬂuency: b = 0.99 (1.78,
0.19), P = 0.015] (Fig. 4A–D).
On the Symbol-Digit Substitution task, the patients got
progressively worse on the task over time [b = 0.79
(1.14, 0.43), P5 0.001], at a similar rate between
groups [b = 0.11 (0.92, 0.70), P = 0.788]. Finally, on
the Letter-Number Sequencing task and the Benton task,
the patients did not show any decline over time [Letter-
Number Sequencing: b = 0.09 (0.18, 0.01), P = .070],
Benton test [b = 0.05 (0.23, 0.14), P = 0.627].
Discussion
The present study is the ﬁrst to assess regional cBF atrophy
in very early stage de novo Parkinson’s disease participants
alongside longitudinal evaluation of cognitive status and
multi-domain cognitive assessment. Our ﬁndings broadly
conﬁrm previous autopsy and in vivo PET studies that im-
plicate the cBF in progressive cognitive decline leading to
dementia in Parkinson’s disease (Bohnen et al., 2003;
Hilker et al., 2005; Shimada et al., 2009). Moreover, we
provide ﬁrst evidence that degeneration in a region corres-
ponding to the NBM can be detected even at very early
disease stages in patients with suspected MCI, and can be
used to predict future development of MCI even in patients
Figure 4 Linear growth curves in cBF and cBF+ patients. Linear growth curves modelled in the cBF versus cBF+ groups (patients
with Parkinson’s disease with reduced volumes in the NBM versus those with volumes within range of controls, respectively). (A–D) A faster
decline over 5 years on the MoCA, delayed and immediate recall on the HVLT, and semantic fluency.
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without current cognitive impairment. These ﬁndings, in
the context of a lack of group-level differences in NBM
volumes between Parkinson’s disease patients and controls
at baseline, conﬁrm substantial heterogeneity of cholinergic
involvement in de novo Parkinson’s disease. Thus, while
such heterogeneity may obscure differences between control
and Parkinson’s disease patients as a whole, our ﬁndings
suggest it can be useful for dissociating Parkinson’s disease
patients at risk for future cognitive impairment and
Parkinson’s disease dementia. Thus, volumetric measure-
ment of the NBM should be evaluated as an additional
parameter alongside combined clinical, genetic, and other
established neuroimaging biomarkers to improve prognos-
tication in Parkinson’s disease-related cognitive decline.
Future work will therefore aim to extend the current ana-
lysis to determine the additional contribution of NBM
volumetry to the recently reported predictive models
(Caspell-Garcia et al., 2017; Schrag et al., 2017) using
the entire PPMI sample.
Given the known involvement of the cBF in Parkinson’s
disease and Parkinson’s disease-related cognitive decline
(Bohnen and Albin, 2009) there is a clear interest in de-
veloping methods to measure degeneration in this brain
region in vivo. Our methods were based on a recently de-
veloped automated morphometry approach that allows
comprehensive assessment of cBF volume based on refer-
ence to a stereotactic map of the cBF nuclei (Grothe et al.,
2012, 2016; Kilimann et al., 2014). In previous studies,
volumetry of the cBF has relied on measurement of the
substantia innominata as a proxy measure. These studies
have revealed reduced substantia innominata volumes from
Hoehn and Yahr stage 2 (Ziegler et al., 2013), in patients
with Parkinson’s disease dementia compared to those with
Parkinson’s disease and MCI (Choi et al., 2012), and in
Parkinson’s disease patients with MCI who subsequently
developed Parkinson’s disease dementia (Lee et al.,
2014b). However, substantia innominata volume does not
appear to reﬂect atrophy occurring in patients with MCI
compared to those without cognitive impairment (Choi
et al., 2012), limiting its use as a predictive marker for
cognitive decline at early disease stages. Thus, our ﬁnding
that atrophy in the NBM can be detected in newly diag-
nosed Parkinson’s disease patients with suspected MCI, can
predict changes in MoCA scores after 2 years across a het-
erogeneously progressing Parkinson’s disease group, and
can be used to prospectively classify patients at risk for
progressive cognitive symptoms, will be of considerable
interest to Parkinson’s disease clinicians and researchers.
Classiﬁcation of at-risk patients based on NBM volumes
at baseline was based on a technique using regression in a
healthy control group to describe expected relationships
between total intracranial volume, age and NBM volumes
alongside a binary classiﬁcation procedure. This allowed us
to deﬁne a group of Parkinson’s disease patients with smal-
ler than expected (given their age and head size) NBM
volumes. Using an arbitrary threshold of 1 SD below the
control range, we found that this group had 3-fold
elevated risk of developing MCI or Parkinson’s disease de-
mentia. Additionally, a linear mixed modelling analysis of
longitudinal year-wise cognitive assessments could corrob-
orate a faster decline on the MoCA over 5-years of follow-
up in those classiﬁed as having reduced NBM volume.
Further work is now necessary in independent samples,
both to corroborate our ﬁndings and to determine the op-
timal thresholds for deﬁning reduced NBM volumes.
It is interesting to note that the region corresponding to
the NBM as whole was most closely associated with future
cognitive impairments, while in Alzheimer’s disease initial
degeneration at the MCI stage (when compared to controls)
seems to be in a region corresponding to the posterior
NBM (Vogels et al., 1990; Grothe et al., 2010, 2012,
2013; Kilimann et al., 2014). Additionally, in the current
paper, Parkinson’s disease patients with suspected MCI,
when compared with controls, had signiﬁcantly different
cBF volumes only in the posterior NBM. This implies
that more severe degeneration in the posterior NBM
region is characteristic of MCI in both Alzheimer’s disease
and Parkinson’s disease, but that future cognitive decline,
at least in Parkinson’s disease, is best predicted by variabil-
ity in the degree of degeneration throughout a more wide-
spread cBF region. Indeed, in Alzheimer’s disease
degeneration spreads to more anterior-medial regions of
the cBF at the time at which patients develop clinically
manifest dementia (Grothe et al., 2012, 2013). On a related
note, the PPMI cognitive battery does not allow subtyping
of MCI types, and the current sample likely includes pa-
tients with forms of MCI that may not herald the onset of
Parkinson’s disease dementia. In future work, it will be
interesting to determine if degeneration in the NBM is sig-
niﬁcantly greater at early disease stages in Parkinson’s dis-
ease patients who develop different forms of MCI, as well
as those who go on to develop Parkinson’s disease demen-
tia. In this regard, our methods may also be informative for
using the degree of cBF degeneration to predict future cog-
nitive decline in patients with prodromal Alzheimer’s
disease.
Whether the involvement of NBM in Parkinson’s dis-
ease reﬂects a shared pathophysiological process with
Alzheimer’s disease warrants further investigation. Schmitz
and Spreng (2016) have recently provided compelling evi-
dence that NBM atrophy precedes degeneration of the
medial temporal lobe in Alzheimer’s disease (a hallmark
of the disease), challenging the prevailing view that
Alzheimer’s disease has a cortical origin, and raising the
possibility that degeneration of the cBF contributes causa-
tively to hippocampal volume losses. Given the known
involvement of the hippocampus in Parkinson’s disease-
related cognitive decline (Weintraub et al., 2011), it
would be useful (both for biomarker development and for
improving our understanding of the disease) to gain similar
insight into the temporal relationships between NBM
and hippocampal degeneration in Parkinson’s disease.
Additionally, in Alzheimer’s disease, there are spatial and
temporal relationships between NBM atrophy and
Cognitive biomarkers in Parkinson’s disease BRAIN 2018: 141; 165–176 | 173
Downloaded from https://academic.oup.com/brain/article-abstract/141/1/165/4712018
by Manchester Metropolitan user
on 10 January 2018
pathological changes in the wider brain (Grothe et al.,
2014, 2016; Teipel et al., 2014; Kerbler et al., 2015;
Kilimann et al., 2017) that are also evident in Parkinson’s
disease patients with cognitive decline (Jokinen et al., 2009;
Apostolova et al., 2012; Gomperts et al., 2013; Gonza´lez-
Redondo et al., 2014; Pereira et al., 2014). Thus, investi-
gation of regional cBF degeneration in Parkinson’s disease
and its relationship with cortical brain changes and
Parkinson’s disease-related cognitive impairments is of
high importance.
In previous work semantic ﬂuency, memory and visuo-
spatial function in early disease stages have been shown to
be associated with later progression to Parkinson’s disease
dementia (Williams-Gray et al., 2009a; Domello¨f et al.,
2015). Using a linear mixed model approach, we also re-
vealed the domain-speciﬁcity of NBM-related changes in
cognitive function over 5 years. While we did not observe
any changes in the group as a whole on the visuospatial
task, individuals classiﬁed as having reduced NBM volumes
did decline more quickly and to a greater degree on the
other preferentially temporal- and posterior cortex-depend-
ant tasks (recall memory and semantic ﬂuency). In contrast,
these patients did not show any differences (to those with
NBM volumes within the expected range) over 5 years on
frontal tasks. Thus, our ﬁndings imply that while not iden-
tical, there are strong similarities between the type of cog-
nitive function affected over time in patients with reduced
NBM volumes at baseline and in patients who eventually
progress to Parkinson’s disease dementia (Williams-Gray
et al., 2009a; Domello¨f et al., 2015). It is important there-
fore that a more ﬁne-grained analysis of the relationship
between NBM degeneration and cognitive function than
is permitted by the PPMI is carried out.
The extent to which our ﬁndings can be reconciled with
previous research on genotype–phenotype associations that
may underlie the cognitive heterogeneity in early
Parkinson’s disease warrants further investigation. Such re-
search has revealed a strong inﬂuence of risk alleles in the
genes encoding for the apolipoprotein E (APOE) and the
microtubule-associated protein tau (MAPT) on cognitive
decline in Parkinson’s disease and the development of de-
mentia (Williams-Gray et al., 2009a, b; Morley et al., 2012;
Mata et al., 2014; Huertas et al., 2017). Additionally, func-
tional MRI studies in patients with early Parkinson’s dis-
ease show an association between these genotypes and
reduced brain activation in medial temporal and parietal
regions during memory and visuospatial tasks, respectively,
but no association with fronto-striatal function (Nombela
et al., 2014; Winder-Rhodes et al., 2015). Notably, both
genotypes have also been linked to faster cognitive decline
and development of dementia in Alzheimer’s disease
(Samaranch et al., 2010; Desikan et al., 2015; Lacour
et al., 2017). However, whether this genetic overlap be-
tween Alzheimer’s disease and Parkinson’s disease links to
a common neuropathological pathway that affects cognitive
decline in both diseases is currently largely unknown. The
ﬁnding that both cBF degeneration and APOE and MAPT
genotypes inﬂuence cognitive decline and progression to
dementia in a transdiagnostic manner warrants further in-
vestigation into their possible neuropathological interrela-
tion. Additionally, given the widespread connectivity of the
cBF, it will be of great interest to understand the link be-
tween genetic risks for Parkinson’s disease dementia, cBF
status, and functional brain networks, analogous to on-
going work aimed at understanding how brain networks
are altered in those with a genetic risk for Alzheimer’s dis-
ease (Teipel et al., 2016).
Our approach for classifying patients with NBM volumes
below the normal range has the potential to translate into
clinical applications. Recent work on multiple modality
biomarkers for Parkinson’s disease-related cognitive decline
has not included a cholinergic biomarker (Caspell-Garcia
et al., 2017; Schrag et al., 2017); yet the current study
implies volumetry of the NBM could be usefully incorpo-
rated. The ability to deﬁne a group of patients at
Parkinson’s disease diagnosis with increased risk of early
development of progressive cognitive impairment leading to
Parkinson’s disease dementia has important implications
for stratiﬁcation of patients in clinical trials of cholinomi-
metics and other treatments, and for understanding the dis-
ease-modifying potential of targeted interventions (Freund
et al., 2009; Rolinski et al., 2012; Gratwicke et al., 2013;
Wang et al., 2015). Further, similar cognitive performance
in patients with reduced cBF volumes at baseline implies
that structural degeneration precedes progressive cognitive
deﬁcits, and the ability to detect this degeneration as
described here offers the opportunity to study Parkinson’s
disease dementia at very early stages of the disease process.
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